Literature DB >> 7369609

Characterization of immune responses of cattle to erythrocyte stroma, Anaplasma antigen, and dodecanoic acid-conjugated Anaplasma antigen: cell-mediated immunity.

D H Francis, G M Buening, T E Amerault.   

Abstract

Sonically disrupted normal erythrocyte stroma (SES) and two anaplasma antigens (sonically disrupted anaplasma antigen; SAA, and French pressure cell disrupted anaplasma antigen; FAA) were prepared from normal and Anaplasma marginale-infected blood. The SAA and FAA antigens were chemically modified by conjugation with dodecanoic acid (SAADA and FAADA). Significant (P less than or equal to 0.05) anti-anaplasma lymphocyte-transformation responses were obtained from all cattle given SAA, SAADA, or FAADA vaccines. Only cows given SAA developed anti-anaplasma antibody. Mild antierythrocyte lymphocyte-transformation responses were obtained from most vaccinated animals. Delayed hypersensitivity to erythrocyte antigen was not detected. The SAA-vaccinated cows had the highest degree of protection in that they developed a smaller percentage of parasitemia and had less severe anemia than did other cattle in the study. The SAADA- and FAADA-vaccinated cattle developed a good cell-mediated immune response, but poor humoral immune response and had lower parasitemias than did challenge-exposed controls; but they developed severe anemia. It is suggested that cellular and humoral mechanisms are essential for protection in anaplasmosis. Evidence of protection from clinical anaplasmosis was not observed in SES-vaccinated cows.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7369609

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  1 in total

1.  CD4(+) T-lymphocyte and immunoglobulin G2 responses in calves immunized with Anaplasma marginale outer membranes and protected against homologous challenge.

Authors:  W C Brown; V Shkap; D Zhu; T C McGuire; W Tuo; T F McElwain; G H Palmer
Journal:  Infect Immun       Date:  1998-11       Impact factor: 3.441

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.